209 related articles for article (PubMed ID: 36067171)
1. Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.
Pogacar Z; Johnson JL; Krenning L; De Conti G; Jochems F; Lieftink C; Velds A; Wardak L; Groot K; Schepers A; Wang L; Song JY; van de Ven M; van Tellingen O; Medema RH; Beijersbergen RL; Bernards R; Leite de Oliveira R
PLoS One; 2022; 17(9):e0273182. PubMed ID: 36067171
[TBL] [Abstract][Full Text] [Related]
2. Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells.
Maskey RS; Wang F; Lehman E; Wang Y; Emmanuel N; Zhong W; Jin G; Abraham RT; Arndt KT; Myers JS; Mazurek A
Cell Cycle; 2021 Jan; 20(1):65-80. PubMed ID: 33356791
[TBL] [Abstract][Full Text] [Related]
3. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
4. Palbociclib-induced autophagy and senescence in gastric cancer cells.
Valenzuela CA; Vargas L; Martinez V; Bravo S; Brown NE
Exp Cell Res; 2017 Nov; 360(2):390-396. PubMed ID: 28947133
[TBL] [Abstract][Full Text] [Related]
5. Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.
Miettinen TP; Peltier J; Härtlova A; Gierliński M; Jansen VM; Trost M; Björklund M
EMBO J; 2018 May; 37(10):. PubMed ID: 29669860
[TBL] [Abstract][Full Text] [Related]
6. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
7. Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells.
Morris-Hanon O; Marazita MC; Romorini L; Isaja L; Fernandez-Espinosa DD; Sevlever GE; Scassa ME; Videla-Richardson GA
Mol Neurobiol; 2019 Nov; 56(11):7810-7821. PubMed ID: 31124078
[TBL] [Abstract][Full Text] [Related]
8. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
[TBL] [Abstract][Full Text] [Related]
9. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract][Full Text] [Related]
10. Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.
Wang H; Yuan S; Zheng Q; Zhang S; Zhang Q; Ji S; Wang W; Cao Y; Guo Y; Yang X; Geng H; Yang F; Xi S; Jin G; Zhang J; Gao Q; Bernards R; Qin W; Wang C
Gastroenterology; 2024 Jun; 166(6):1130-1144.e8. PubMed ID: 38262581
[TBL] [Abstract][Full Text] [Related]
11. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
Yoshida A; Lee EK; Diehl JA
Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
[TBL] [Abstract][Full Text] [Related]
12. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Jin X; Ge LP; Li DQ; Shao ZM; Di GH; Xu XE; Jiang YZ
Mol Cancer; 2020 May; 19(1):87. PubMed ID: 32393270
[TBL] [Abstract][Full Text] [Related]
13. p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer.
Rampioni Vinciguerra GL; Dall'Acqua A; Segatto I; Mattevi MC; Russo F; Favero A; Cirombella R; Mungo G; Viotto D; Karimbayli J; Pesce M; Vecchione A; Belletti B; Baldassarre G
Cell Death Dis; 2021 Oct; 12(10):951. PubMed ID: 34654798
[TBL] [Abstract][Full Text] [Related]
14. Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
Clark AS; Karasic TB; DeMichele A; Vaughn DJ; O'Hara M; Perini R; Zhang P; Lal P; Feldman M; Gallagher M; O'Dwyer PJ
JAMA Oncol; 2016 Feb; 2(2):253-60. PubMed ID: 26633733
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.
Hsieh FS; Chen YL; Hung MH; Chu PY; Tsai MH; Chen LJ; Hsiao YJ; Shih CT; Chang MJ; Chao TI; Shiau CW; Chen KF
Mol Oncol; 2017 Aug; 11(8):1035-1049. PubMed ID: 28453226
[TBL] [Abstract][Full Text] [Related]
16. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Chen F; Liu C; Zhang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
[TBL] [Abstract][Full Text] [Related]
17. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
18. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells.
Min A; Kim JE; Kim YJ; Lim JM; Kim S; Kim JW; Lee KH; Kim TY; Oh DY; Bang YJ; Im SA
Cancer Lett; 2018 Aug; 430():123-132. PubMed ID: 29729292
[TBL] [Abstract][Full Text] [Related]
19. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
[TBL] [Abstract][Full Text] [Related]
20. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]